Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced ...

The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...

The ability of mutations to cause cancer depends on how fast they force cells to divide, Sinai Health researchers have found. The study, led by Dr. Rod Bremner, a Senior Investigator at the ...

A precision cancer strategy that selectively kills tumour cells while leaving healthy tissue intact may be within reach for the majority of colorectal cancer patients, according to new research ...

The Purvalanol A (CDK Inhibitor) market has demonstrated impressive growth, expanding from $0.64 billion in 2025 to $0.7 ...

An octopus-shaped nanomachine hijacks tumor ATP leakage to power a self-amplifying cycle of membrane damage, drug delivery, and metabolic collapse in cancer cells.

In this segment, Dr. Gregory Vidal explains why CDK4/6 inhibitors are commonly added to endocrine therapy in the treatment of ...

A metabolic enzyme found in the support cells surrounding tumors may hold the key to predicting which cancer patients will ...